Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Despite an R&D spend of around $15bn, a total of 20 beta amyloid protein-targeting drugs have failed to show efficacy in phase II and III studies involving AD patients, and pharma companies are ...

The ratio of two proteins that help brain cells communicate with each other may be a stronger indicator for cognitive ...

The tau isoform 1N4R confers vulnerability of MAPT knockout human iPSC-derived neurons to amyloid beta and phosphorylated tau-induced neuronal dysfunction, Alzheimer's & Dementia (2025).

A recent study published in Brain Communications has shed light on how traumatic brain injuries, such as those experienced in combat or accidents, might influence the development of brain changes ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – ...

Trontinemab is currently being studied in the Phase Ib/IIa Brainshuttle AD study assessing the safety, tolerability, ...

(CNN) — For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can ...

An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to form plaques that collect between neurons and disrupt cell function.